In the setting of low-flow/low-gradient aortic stenosis (LF/LGAS), outcomes of pseudo-severe aortic stenosis (AS) remain poorly described. This study was aimed to assess the outcome of patients with pseudo-severe AS under conservative treatment.
Introduction
Low-flow/low-gradient aortic stenosis (LF/LGAS) refers to patients with presumably severe aortic stenosis (AS) and low transaortic pressure gradients due to left ventricular (LV) systolic dysfunction. 1, 2 This rare subgroup (5-10% of patients with AS) remains a common medical challenge due to high operative mortality and a dismal prognosis under conservative treatment. Furthermore, some patients with LF/LGAS may have intrinsic myocardial dysfunction with only moderate AS. 1,3 -5 In this case, referred to as pseudo-severe AS, patients may not respond favourably to aortic valve replacement, which is not recommended by current guidelines. 1, 2 On the other hand, available studies universally report a poor outcome of LF/LGAS under conservative treatment, including for some patients with pseudo-severe AS. 4, 5 Some authors have even questioned the benefits of conservative treatment in pseudo-severe AS, suggesting that moderate AS might be harmful in case of severe LV dysfunction. 6, 7 Of note, outcome data regarding pseudo-severe AS remain scarce and further studies are urgently needed. This study was aimed at assessing outcomes under conservative treatment among patients from the European multicentre registry of LF/LGAS. Our hypothesis was that under conservative treatment, patients with pseudo-severe AS might have a more favourable outcome than patients with true-severe AS. . 4 Exclusion criteria were: severe extra cardiac comorbidities (life expectancy shorter than 1 year), more than mild aortic or mitral regurgitation, and atrial fibrillation. Follow-up data were prospectively collected at each centre. Data from this multicentre European registry were previously published, mainly focused on outcomes after surgery 8 or patients without LV contractile reserve. 9, 10 The present study is based on the 107 consecutive patients who were followed under conservative treatment for .6 months and focused on pseudo-severe AS. The study was approved by local institutional review boards and informed consent was obtained from each patient before all procedures.
Methods Population
Between
Data collection
Baseline demographic and clinical and echocardiographic data were prospectively collected. All patients underwent a dobutamine stress echocardiography (DSE), using commercially available ultrasound systems. Transaortic gradients were calculated using the simplified Bernoulli equation, the AVA was calculated by the continuity equation and the LVEF was calculated according to biplane Simpson's rule or visual estimation. Details of the DSE protocol have been previously described. 11 The Logistic EuroSCORE (available at http://www. euroscore.org) was calculated in all patients.
Coronary angiography
Coronary angiography was performed in 81 patients (76%). Significant CAD was defined by a reduction in diameter ≥70% for all coronary arteries, except for the left main coronary artery, for which a threshold of ≥50% was considered. Multivessel CAD was defined as the presence of significant stenosis on ≥2 vessels.
Analysis of the dobutamine stress echocardiography studies
Dobutamine echocardiographic studies were evaluated off-line in each centre by a single-experienced echocardiographer. All data from each centre were then centralized for statistical analysis. The left ventricular contractile reserve was defined by an increase in the stroke volume of ≥20% under dobutamine infusion, when compared with baseline.
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Patients were classified according to the presence (group I) or absence (group II) of the LV contractile reserve. 12 Pseudo-severe AS was defined by a final AVA ≥1.2 cm 2 with an MPG ,40 mmHg at peak-dobutamine infusion. 1, 5 Accordingly, group I was further divided into group IA (true-severe AS) and group IB (pseudo-severe AS). For the whole cohort (n ¼ 305), the distribution of patients according to treatment (surgery vs. conservative) and groups (IA, IB, and II) is shown by Figure 1 . cance between group IB and the others was examined if there was a significant difference across categories. The seven group-IB patients who eventually underwent surgery were analysed as group-IB patients throughout the study under the 'intent-to-treat' assumption. P-values were not adjusted for multiple comparisons, and therefore are provided only for descriptive purposes. Survival curves were generated using the Kaplan-Meier method. The outcome of group IB, compared with other groups, was investigated with the use of Cox proportionalhazards regression in three models: a crude model, a model adjusted for established risk factors for AS (EuroSCORE and MPG), and a model adjusted for established risk factors and baseline parameters that were significantly different between the three groups (with a P-value , 0.05). Proportional-hazards assumption was confirmed using test and graphs based on Schoenfeld residuals. We used propensity score analysis to match patients with pseudo-severe AS (group IB) with a population of patients with systolic heart failure (HF), LVEF ,50%, and no evidence of significant valvular disease. 13 Propensity scores for pseudo-severe AS were estimated using a multivariable logistic model in a forward stepwise regression analysis, as previously described. 10, 14, 15 The variables included in the logistic model were age, sex, NYHA class, CAD, history of myocardial infarction, hypertension, diabetes mellitus, and LVEF. We used an SPSS macro 16 to match patients with pseudo-severe AS and patients in the HF group with a propensity score within 4%. Twenty-eight patients with pseudo-severe AS were successfully matched with 28 HF patients. The distribution of categorical variables between the two groups in the matched cohort was compared with the use of the McNemar test. Continuous variables were compared between groups in the matched cohort using paired t-tests or Wilcoxon-signed rank tests, as appropriate. The success of the propensity score matching was assessed by checking standardized differences between groups after matching, i.e. the absolute difference in sample means divided by an estimate of the pooled standard deviation of the variable, expressed as a percentage. Balancing was considered as successful, if the standardized differences were ,10%. In the matched cohort, Kaplan-Meier survival curves were estimated for patients with pseudo-severe AS and for HF patients. The survival curves of matched patients were compared according to methods appropriate for matched data. 17 For all tests, a P-value , 0.05 was considered statistically significant. All P-values are the results of two-tailed tests. Statistical analysis was performed with SPSS 13.0 (SPSS, Inc., Chicago, IL, USA) and STATA version 9.0 (Stata Corp, College Station, TX, USA).
Results

Baseline characteristics of patients and dobutamine stress echocardiography results
The 107 patients with LF/LGAS managed conservatively were aged 76 years (69 -81) and 24 of them were female (22%). Severe symptoms were reported in all cases, including class III -IV dyspnoea (n ¼ 84, 79%), angina pectoris (n ¼ 11, 10%), or syncope (n ¼ 2, 2%). Twenty-nine patients (27%) met the criteria of pseudo-severe AS (group IB). Baseline medical treatments were available in 74 patients, including diuretics (n ¼ 68), ACE inhibitors/angiotensinreceptor blockers (n ¼ 56), beta-blockers (n ¼ 24), or digoxin (n ¼ 8). Baseline characteristics and main DSE results according to groups are presented in Table 1 . In group IB, the proportion of male patients was significantly higher, baseline MPG was slightly lower, and baseline AVA significantly larger compared with the other groups. Peak-dobutamine MPG remained ,30 mmHg in 22 patients from group IB, whereas it increased to 30 -40 mmHg in seven patients. In group IA, peak-dobutamine AVA remained ,1.2 cm 2 in all patients (by definition). Peak-dobutamine MPG was ≥40 mmHg in 12 patients; it was 30-39 mmHg in 18 patients and ,30 mmHg in 13 patients.
Clinical outcomes in pseudo-severe aortic stenosis
Among 29 patients under conservative treatment, the follow-up LVEF was available in 13 patients, showing an average increase from 27% (20 -38) to 35% (29-45) (P ¼ 0.075). Aortic valve replacement was eventually performed in seven patients (including associated CABG in one case) after 18 months (11-46) of conservative follow-up. The reason for surgery was progression to severe AS in three of these patients after 29, 64, and 65 months, respectively, and one patient died postoperatively. The remaining four patients were operated on for the lack of clinical improvement under conservative treatment after 7-18 months of follow-up and three of them died postoperatively. Univariate predictors of death under conservative management are given in Table 2 . The median follow-up was 12 (11-33) months for patients who died during the follow-up and 17 (23 -60) months for patients alive at follow-up. By multivariable analysis, the two independent predictors of death among pseudo-severe AS patients were associated CAD [hazard ratio (HR), 1.88; 95% confidence interval (CI), 1.35-2.63; P , 0.001] and a baseline mean pressure gradient ,20 mmHg (HR: 1.55; 95% CI: 1.07-2.23; P ¼ 0.02). Although it was not the aim of the present analysis, the outcome of the nine additional patients with pseudo-severe AS who initially underwent surgery is given for comparison. The main reason for surgery was the presence of significant CAD in five patients or an ascending aorta aneurysm in two patients, whereas it was not clearly stated for the two remaining patients. The operative mortality was 11% (one patient) and the 5-year survival rate was 71 + 18% in this small subgroup.
Comparison of outcomes according to dobutamine stress echocardiography results
At the latest follow-up for the whole cohort, 74 patients had died (69%) at a median interval of 10 months (range 4-21 months), mostly from cardiac causes (n ¼ 60 patients, 81% of all deaths).
The following causes of death were reported: congestive HF (n ¼ 45), sudden death (n ¼ 15), pulmonary disease (n ¼ 4), cancer (n ¼ 2), stroke (n ¼ 1), renal failure (n ¼ 1), or unknown cause (n ¼ 6). Kaplan -Meier survival estimate by group is shown by Figure 2 : the rate of death by 5 years was significantly lower in group IB (43 + 11%, n ¼ 10), when compared with group IA (91 + 6%, n ¼ 33; P ¼ 0.001) and group II (100%, n ¼ 23; P , 0.001). There was no survival difference between groups IA and II (P ¼ 0.62). The Cox proportional hazard analysis demonstrated that the hazard ratio for death in group IB remained significantly lower than that of the other two groups (Model 1, Table 3 ), even after adjustment for currently established risk factors in LF/
LGAS (EuroSCORE and baseline mean transaortic pressure gradient, Model 2, Table 3 ) or adjustment for established risk factors and gender (Model 3, Table 3 ). By propensity-score matching, 28 of the 29 patients with pseudo-severe AS were successfully matched with 28 patients with systolic HF and no evidence of valvular disease. The characteristics of patients in group IB and patients with systolic HF before and after matching are presented in Table 4 . After matching, no difference in the baseline variables was observed between the two groups. In the 28 matched pairs, the 5-year survival was 52 + 11% for the pseudo-severe AS group and 44 + 10% for HF patients (Figure 3) . The difference was not statistically significant (P ¼ 0.41).
Discussion
Current guidelines state that dobutamine echocardiography is reasonable to evaluate patients with LF/LGAS in order to assess LV contractile reserve and to distinguish true-severe AS from pseudosevere AS. mainly due to afterload mismatch and these patients may respond favourably to valve replacement. Conversely in pseudo-severe AS, LV dysfunction is mainly due to intrinsic myocardial disease with only moderate AS and these latter patients may not benefit from surgery. 1,2 However, the dismal prognosis of LF/LGAS under conservative treatment is widely recognized and despite an overall high operative risk, most studies have demonstrated a substantial benefit of valve replacement over conservative treatment in the majority of patients. 3, 4, 9, 10, 18 Therefore, some authors have questioned the benefits of conservative treatment in pseudo-severe AS, suggesting that even moderate AS might be harmful in the setting of severe LV dysfunction. 6, 7 Finally, available data regarding outcomes in pseudo-severe AS remain scarce, with only 10 consecutive patients in the largest series reported by Zuppiroli et al. 19 To the best of our knowledge, we report here the largest series of patients with LF/LGAS followed under conservative treatment. Our main result is that the 5-year outcome under conservative treatment is better in the case of pseudo-severe AS than in true severe AS or in patients without LV contractile reserve. Furthermore, the 5-year survival under conservative treatment is comparable between patients with pseudo-severe AS and propensity-matched patients with systolic HF.
Definition and incidence of pseudo severe aortic stenosis
In the pioneering study by deFilippi et al., 12 pseudo-severe AS (defined by a dobutamine increase in AVA ≥0.3 cm 2 ) was reported in 5/18 patients with a dobutamine AVA .1.0 cm 2 in all cases.
Conversely, in the series by Nishimura et al. 5 nine patients had a severely calcified aortic valve at surgical inspection despite a dobutamine AVA .1.0 cm 2 . Therefore, these authors suggested to define pseudo-severe AS by an AVA .1.2 cm 2 with a mean transaortic gradient ,30 mmHg at peak dobutamine infusion. 5 To overcome the limitations of DSE for assessing the severity of AS in case of poor LV contractile reserve, the TOPAS group introduced the , which is higher than the projected AVA value in the same patients (1.1 + 0.2 cm 2 ). Based on these data, we consider that a dobutamine-AVA ≥1.2 cm 2 is a reliable cut-off to define pseudosevere AS. 3, 5 Furthermore, in the present series, the mean transaortic gradient at peak dobutamine infusion remained ≤40 mmHg in all patients classified as pseudo-severe AS, supporting the use of this cut-off. In previous studies, the incidence of pseudo-severe AS varied widely from 5 to 27%, 4,5,12,19 -21 when compared with 11% in the present study. In the recent study from TOPAS, the incidence of pseudo-severe AS was 27% (14/ 52 operated patients). 20 Of note, patients included in the TOPAS registry had a baseline AVA ≤1.2 cm 2 , when compared with a baseline AVA ≤1.0 cm 2 in the present registry. Thus, the lower incidence of pseudo-severe AS in our registry may be related, at least in part, to the different inclusion criteria or to definitions used for pseudo-severe AS in the previous studies.
12,20
Outcomes of pseudo-severe aortic stenosis under conservative treatment
The mortality rate under conservative treatment was 20 -25% in two initial studies including relatively small numbers of patients. 12, 21 However, the average duration of follow-up was only 11-12 months in these studies. 12, 21 In the study by Nishimura et al., 5 11 patients with LF/LGAS were followed conservatively, 7 of whom were classified as pseudo-severe AS. Despite an AVA .1.2 cm 2 or a mean transaortic gradient ,30 mmHg at peak dobutamine, mortality under conservative treatment was at least 57% after 32 months (the exact number was not available). Mortality rates under conservative treatment were 50 and 70% in two other studies after 19 and 24 months of follow-up. 4, 19 Thus, based on these latter studies, mortality under conservative treatment was obviously higher in pseudo-severe AS than in patients with primary cardiomyopathy and similarly advanced LV systolic dysfunction. 22 Based on these data, some authors have questioned the clinical relevance of detecting pseudo-severe AS, suggesting that even moderate AS might have a negative prognostic impact in case of severe LV systolic dysfunction. 6, 7 This hypothesis was further supported by the negative impact of moderate prosthesispatient mismatch in case of low ejection fraction reported in some studies. 23, 24 In contrast, we found in the present study that 24-month mortality under conservative treatment was significantly lower in pseudo-severe AS (28%), as compared to patients with true-severe AS (60%, P ¼ 0.008) or those without LV contractile reserve (63%, P ¼ 0.04). Furthermore, after propensity-score matching of 28 patients with pseudo-severe AS with 28 patients with systolic HF and no evidence of valvular disease, the 5-year survival was not significantly different between these groups. Of note, our results are supported by a report from the TOPAS Group, in which a projected AVA ,1.2 cm 2 was predictive of mid-term survival, only if patients were managed conservatively. 20 Taken together, these data provide convincing evidence that the distinction between pseudo-severe AS and true-severe AS is clinically relevant, as suggested in current practice guidelines.
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Study limitations
The first limitation is the relatively small number of patients with pseudo-severe AS under conservative treatment included in this study. However, to the best of our knowledge, no larger consecutive series has been reported to date. Of note, the incidence of pseudo-severe AS represents 10 -15% of patients with LGAS, that is 1% of all patients with AS; this may explain why large consecutive series of such patients have not been reported. The observational nature of the study could also appear as a limitation. However, given the overall poor prognosis of LF/LGAS under conservative treatment, randomized studies in this setting would neither be ethical nor feasible. In addition, the fact that most centres did not collect detailed information regarding medical treatments during follow-up could also appear as a limitation. The decision of conservative management was taken by the referring physician, thus the selection bias of high-risk patients with true-severe AS in the conservative group cannot be excluded. However, despite fairly comparable baseline risk profiles according to groups (Table 1) , multivariable analysis strongly supports the fact that the outcome under conservative management was significantly better in pseudo-severe AS compared with the other groups ( Table 3) . In group I, despite the peak-dobutamine AVA ,1.2 cm 2 in all patients, peak-dobutamine MPG remained in the range of 30 and 39 mmHg in 18 patients and ,30 mmHg in 13 patients. One cannot fully eliminate some cases of pseudo-severe AS among these patients. The use of projected AVA might overcome this limitation of DSE 20 but such data were not available for the present study. Furthermore, given the progressive nature of AS, serial DSE may have a role in the follow-up of patients under conservative treatment. Unfortunately, the results of any repeated DSE are not available in our database. The significant difference in the baseline AVA between true-severe AS vs. pseudo-severe AS may suggest that the latter might be detected at baseline (i.e. without a dobutamine challenge). However, the borderline value of AVA at baseline is part of the definition of pseudo-severe AS and its dynamic increase under dobutamine may overcome the limitations of AVA calculation at baseline in the setting of low-flow/low-gradient. 5, 12 Finally, DSE does not allow distinguishing pseudo-severe from true-severe AS in the group of patients without contractile reserve. In this latter group, the quantification of valve calcification by multislice computed tomography may be useful to overcome this limitation of DSE. 25 Unfortunately, the quantification of aortic valve calcification was not performed in the present study.
Conclusions
Among a series of 107 patients with LF/LGAS followed under conservative treatment, we found that the 5-year survival rate was significantly better in case of pseudo-severe AS than in patients with true-severe AS or those without LV contractile reserve. Furthermore, the 5-year survival of pseudo-severe AS patients was fairly comparable with that of propensity-matched patients with systolic HF and no evidence of valve disease. Therefore, our results provide direct evidence that the distinction between pseudosevere AS and true-severe AS is clinically relevant in the setting of LF/LGAS. Further studies are needed to define the best therapeutic approach in this rare subset of patients.
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